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Supplemental Results
Demographics
Five cohorts were included in this study: Two clinical cohorts (asthma cases only), the Genetics of
Severe Asthma Phenotypes (GASP) (1), and Dutch Asthma Genetics (DAG) (2); two population based
cohorts (providing asthma cases and controls), the Manchester Asthma and Allergy Study (MAAS) (3)
and the Lifelines Cohort Study (4) and the Nottingham Gedling Cohort (5) (providing controls only).
General characteristics of cohorts are represented in Supplemental Tables 1-3. The GASP cohort
provided 2,536 cases where genotypes were available for analyses. This cohort had a mean subject age
of 47.8 years, a mean age of asthma onset of 23.2 years (46.2% being diagnosed with asthma before the
age of 16 years) and 46.8% atopic prevalence. The DAG cohort provided 909 cases with genetic data,
with a mean age of 34.8 years, mean age of asthma onset of 10.1 years (57.2% being diagnosed with
asthma before the age of 16 years) and 63.7% atopic prevalence. The MAAS included 919 children
with available genotypes, presenting with a mean age of 8 years, (23.9% being diagnosed with asthma)
and 32.9% atopic prevalence. The Lifelines cohort included 1066 asthma cases (mean age 46.2 years)
and an additional 6,863 controls (mean age 49.2 years); no data was available for atopic status, total
IgE or onset of asthma. The Nottingham Gedling cohort provided 200 non-asthmatic controls (mean
age 57).
Association of IL1RL1 variants with characteristics of asthma
In our Stage 1 analyses (Figure 1) we identified 461 SNPs associated with one or more of the asthma
related traits across the association analyses using the initial FDR<0.05 screen. In particular, 130 SNPs
showed association with asthma diagnosis and 316 with blood eosinophil counts in the general
population in the LifeLines cohort (Supplemental Tables 8 & 9). This consisted of two signals (r2>0.1)
each contained within its own LD block, where both signals were common to both asthma diagnosis
and eosinophil levels in a general population (rs12474258 (IL1RL2 intronic) (T): Asthma; OR=1.20
(SE 0.05), FDR=0.049, Eos Counts; Beta=0.027 (SE 0.008), FDR=0.017; rs72823628 (IL1RL1
intronic) (G): Asthma OR=1.38 (SE 0.09), FDR=0.049, Eos Counts; Beta=0.013 (SE 0.013),
FDR=0.046). Significant overlap was observed between asthma associated SNPs and SNPs associated
with eosinophil levels in a general population (please refers to Supplemental Table 8). Similarly, 4
SNPs showed association with atopy in a meta-analysis of the GASP & DAG cohorts (Sentinel SNP:
rs2041747 (IL1R1) (A) meta-analysis; Beta =-0.63 (SE 0.19), P=7.81E-04). This consisted of a single
signal (r2>0.1) (Supplemental Table 3). However this signal did not achieve later criteria of MAF≥0.1 
and was therefore not taken forward. An additional two association signal consisting of a single SNP
each at FDR<0.05, was also observed for lung function (FEV1) in the meta-analysis (Sentinel SNP:
rs4142132 (IL1RL1 intronic) (A); Beta=-0.07 (SE 0.02), FDR=0.029; Sentinel SNP: rs113238379
(SLC9A2 intronic) (A); Beta=-0.21 (SE 0.07), FDR=0.049) (Supplemental Table 7). However the signal
tagged by rs113238379 did not achieve later criteria of MAF≥0.1 and was therefore not taken forward. 
Overall this identified 2 independent signals across the asthma-subtypes consisting of two or more SNPs
in LD. Association testing in the childhood cohort (MAAS) for lung function and atopy phenotypes
evaluated 2,206 SNPs for association and identified no signals meeting initial criteria of an FDR less
than 5%.
To identify novel variants, including potentially rare variants, we undertook two sequencing
approaches. By resequencing the exons and additional regions of IL1RL1 in 94 asthma patients using
Sanger sequencing we identified 56 variants (Supplemental Table 3) with 14 resulting in amino acid
changes within IL1RL1. Of these 56 SNPs, 40 were common and 16 rare (Minor Allele Frequency
[MAF]<0.05) in our adult asthma population (N=94) (see Supplemental Table 3). No novel SNPs were
identified. Using a complimentary approach that also integrates intronic and intergenic regions, in
parallel we enriched the entire chromosome 2q12 locus for region based sequencing using DNA from
200 severe asthma subjects and 2000 non-asthmatic, non-atopic control subjects. These analyses
identified 4,107 variants spanning the region (Supplemental Table 1); including 51 variants (37 non-
synonymous, 14 synonymous) in the coding regions of IL18R1, IL18RAP, IL1R1, IL1RL1, IL1RL2 &
SLC9A4 with nine coding region variants in the IL1RL1 gene (Supplemental Table 1). Additional
variation including structural variation e.g. insertion/deletions spanning the region were also identified
(Supplemental Table 1).
Using region based sequencing data generated in the case/control cohort we completed an association
analysis for severe asthma as an outcome using sequencing allele counts. Using the same initial
screening of association (FDR<0.05) we identified 8 variants meeting criteria (Supplemental Table 2).
This included a novel SNP at location chr2:103141056 (C|T) with a population frequency of 0.0271.
The most significant variant, a previously unreported signal; rs35404747 (IL1R1), generates an insertion
(C/CCTT), case MAF: 0.0009; control MAF: 0.1093, FDR=8.21E-08 (Supplemental Table 2).
However, the only variant to achieve later criteria of (MAF≥0.1) was rs72825929 (5` SLC9A4), (A),
case MAF: 0.08; control MAF: 0.18, FDR=0.035 (Supplemental Table 2).
IL1RL1 SNPs were not identified as eQTLs in airway wall biopsies in healthy subjects
Next, we extended eQTL analysis to bronchial brushings and biopsies to test whether the selected
signals are associated with IL1RL1 expression in airway wall. Examination of the four priority signals
for effects on IL1RL1 expression in bronchial brushings (n=72) as well as in bronchial biopsies (n=77)
of healthy volunteers, however, did not identify any eQTLs (Supplemental Table 14).
Supplemental Methods
Cohorts
Genetics of Asthma Severity and Phenotypes (GASP) cohort
Asthmatic individuals aged 16-60 were recruited from across the United Kingdom as part of an Asthma
UK initiative to generate a cohort that is enriched for patients with British Thoracic Society Step 3 and
above (moderate-severe asthma) (6). Subjects had extensive clinical characterisations (Supplemental
Table 10). Asthma was defined as a doctor’s diagnosis of asthma through the presence of symptoms
and medical treatment, while age of onset of asthma was determined through patient records. Asthma
related clinical traits used in the current study focussed to lung function (FEV1, FEV1/FVC), atopic
status (positive skin prick test), Blood Eosinophil Count (x109/L) and Blood IgE levels (KU/L). Lung
function tests for FEV1 and FVC were carried out through spirometry using a Vitalograph Medisoft
BB5500 Whole Body Plethysmography System. Total peripheral blood eosinophil levels were
calculated using a counting chamber while total Immunoglobulin E (IgE) levels were measured by
ImmunoCAP™. Finally, atopy was defined as a positive response to a skin prick test (SPT) to any
allergen from a panel of 4-24 allergens.
Dutch Asthma GWAS (DAG) cohort
The DAG cohort consists of 469 trios (patient – spouse – child) ascertained through a proband with
asthma, combined with an additional case-control study of 452 asthmatics and 511 controls (2). Of
these, we selected 909 asthma patients who underwent the same, standardized, comprehensive
evaluation for asthma at Beatrixoord Hospital, Haren, The Netherlands between 1962-2000. Asthma
was defined as a doctor’s diagnosis of asthma, asthma symptoms, and presence of bronchial hyper-
responsiveness (BHR). FEV1 was measured using a water-sealed spirometer (Lode Spirograph type DL,
Lode b.v., Groningen, The Netherlands). Total peripheral blood eosinophils were counted in a counting
chamber and IgE levels were measured in serum by an enzyme-linked fluorescence assay (Mini Vidas,
Biomerieux Inc., Marcy, France). In subjects older than 12 years, intracutaneous tests with 16 common
aeroallergens were performed. In children younger than 12 years, a skin prick test was performed with
10 allergens. Subjects with a positive response to one or more intracutaneous or skin prick tests were
considered to be atopic. Age of asthma onset was based on data from medical records and
questionnaires, indicating the start of asthma symptoms (Supplemental Table 10). A representative
subset (n=95) of the DAG cohort was taken for resequencing the IL1RL1 region, and consisted of
asthma patients of moderate severity, as shown in Supplemental Table 11.
Lifelines Cohort
Lifelines is a multi-disciplinary prospective population-based cohort study examining in a unique three-
generation design the health and health-related behaviours of 167,729 persons living in the North of
The Netherlands. It employs a broad range of investigative procedures in assessing the biomedical,
socio-demographic, behavioural, physical and psychological factors which contribute to the health and
disease of the general population, with a special focus on multi-morbidity and complex genetics. The
cohort profile of the Lifelines study has been extensively described previously (4) (see Table 1 for sub-
set used in this analysis). Participant baseline visit took place between December 2006 and December
2013. All general practitioners in the three northern provinces of the Netherlands were asked to invite
their registered patients aged 25–49 years. All persons who consented to participate were asked to
provide contact details to invite their family members (i.e., partner, parents and children), resulting in a
three-generation study. Baseline data were collected from 167,729 participants, aged from 6 months to
93 years. Collected data include physical examinations, DNA, blood and urine samples, and
comprehensive questionnaires on history of diseases, quality of life, lifestyle, individual socioeconomic
status, work, psychosocial characteristics and medication use. Follow-up is planned for at least 30 years,
with questionnaires administered every 1.5 years and a physical examination scheduled every 5 years.
At current, a subset of the adult participants have genomewide genotype information available
(n=13,395), numbers still increasing with each novel release of Lifelines every couple of years.
Lifelines is a facility that is open to all researchers. An overview of the available data and application
procedure is presented online, accessible via www.lifelines.nl.
Manchester Asthma and Allergy Study (MAAS) cohort
MAAS is a birth cohort study which follows the development of both asthma and other atopic disorders
in a population based birth cohort. Subjects were recruited in the maternity catchment area of
Wythenshawe and Stepping Hill Hospitals, comprising 50 square miles of South Manchester and
Cheshire, United Kingdom (Supplemental Table 13). Clinical follow up took place at age 8 years. FEV1
and FVC were measured according to the American Thoracic Society guidelines (7) using a
pneumotachograph based spirometer using incentive animation software (Jaeger, Germany). The test
was repeated at intervals of 30 seconds until 3 technically acceptable traces were obtained and the
highest FEV1 was recorded. Atopy was defined as a positive skin prick test (mean weal diameter 3mm
greater than negative control) to at least one of the allergens tested (Mite, cat, dog, grass pollen, milk,
egg, mixed moulds, tree pollen, peanut). Asthma was defined as parental report to the question “has
your child ever suffered from asthma?”
Lung Tissue Cohort
Non-tumor containing lung tissue was collected from patients who underwent lung resection surgery at
three participating sites: Laval University (Quebec, Canada), University of British Columbia
(Vancouver, Canada) and University Medical Center Groningen (Groningen, The Netherlands). Cohort
characteristics have been described previously (8).
Normal Values of Inflammatory Variables From Healthy Subjects (NORM) cohort
77 respiratory healthy subjects were derived from the Normal Values of Inflammatory Variables From
Healthy Subjects (NORM) study (NCT00848406 (9, 10)). Current smokers and never smokers older
than 18 years were recruited into this study. Subjects were considered respiratory healthy if they had no
respiratory symptoms, no history of respiratory disease and normal pulmonary function. Normal
pulmonary function was defined as a post bronchodilator FEV1/FVC higher than lower limit of normal,
absence of AHR to methacholine (PC20 <16mg/mL) and absence of reversibility (FEV1 %predicted to
Salbutamol < 10%). Subjects were excluded if they used inhaled or oral corticosteroids within the last
5 years, or for a period of 5 years or longer.
The Asthma Human Bronchial Epithelial Cell (AHBEC) cohort
The asthma human bronchial epithelial cell (AHBEC) cohort consists of primary bronchial epithelial
cells from 33 individuals with a doctor’s diagnosis of asthma recruited from Nottingham and Leicester.
Cells were obtained through endobronchial biopsies and brushes carried out as per standard procedure
(11, 12). These cells were used for all primary human cell culture, as described. Clinical characterization
of these patients included lung function tests for FEV1 and FVC. Total peripheral blood eosinophil
levels were calculated using a counting chamber (Supplemental Table 15).
Functional characterisation of IL1RL1 variants in primary bronchial epithelial cells
Cell culture and collection of RNA and protein lysate.
Passage 2/3 HBECs obtained from bronchial brushes and biopsies from the AHBEC cohort as
previously described (13), were cultured on PureCol Type-I Bovine collagen (Advanced BioMatrix,
5005-B) in fresh growth factor-supplemented medium (BEGM, Lonza). BEGM was changed to basal
medium 24 hours prior to stimulation with either HDM (50µg/ml) (Greer XPB70D3A25 (Lot: 23187)),
human recombinant IL-33 (50ng/ml) (Abnova, P3638) or PBS as a vehicle control. For stimulation with
RV16 (Public Health England), BEGM was changed to infection medium (BEGM-I), i.e. BEGM
lacking Bovine Pituitary Extract, 24 hours prior to infection with a virus MOI of 1. Cells were infected
for a period of 1 hour, following which they were washed three times with sterile PBS and fresh BEGM-
I was added. Cells were then incubated for 24 hours. Protein and RNA lysates were collected as
previously described (14).
Quantitative PCR
HBEC complimentary DNA (cDNA) was synthesised from 1µg RNA using Superscript II (Invitrogen,
UK) and random hexamer primers according to the manufacturer’s instructions. TaqMan® Quantitative
PCR (qPCR) was then utilised to quantify mRNA levels of IL1RL1 and was performed and analysed as
previously described (14).
Genotyping of primary bronchial epithelial cells
DNA was extracted using the Qiagen QIAamp® DNA Mini and Blood Mini Kit according to the
manufacturer’s instructions. SNP Genotyping was then carried out using TaqMan® Pre-designed
assays.
Quantification of soluble IL1RL1 protein levels.
Soluble IL1RL1 in cellular supernatants was measured using Luminex assays (supplied by R&D,
product code LXSAHM) according to the manufacturer’s recommendations using a custom Magnetic
Luminex Screening Assay with a Human Premixed Multi-Analyte Kit (R&D systems). Each
experimental supernatant was assayed in duplicate.
Functional characterisation of IL1RL1 coding region variants using recombinant expression
Preparation of IL1RL1 coding region transfection plasmids.
The open reading frame of membrane IL1RL1 containing the exon 11 asthma protective/risk haplotypes
for the TIR domain haplotype was amplified from mRNA to generate two expression cassettes
containing either; Ala433-Glu501-Thr549-Leu551 or Thr433-Arg501-Ile549-Ser551 haplotypes.
Primers including a consensus Kozak sequence and restriction enzyme sites: 5’primer: 5’-
ACTTGCTAGCGCCACCATGGGGTTTTGGATC-3’ and 3’ primer: 5’-
ACTTGCGGCCGCCTATTGCTTCTGG GCAGCC -3’. The PCR products were cloned into the
pGEM®-T Vector System II (Promega A1380), subcloned (NheI and NotI) into pCDH-CMV-MCS-
EF1-copGFP (SBI) and sequence verified.
IL1RL1-HEK Reporter cells system.
HEK293 cells genetically modified to contain an NF-KB Secreted Alkaline Phosphatase Reporter
(NovusBio NBP2-26260), were cultured in DMEM containing 4.5 g/L -glucose and 4 mM L-glutamine
(Sigma D5796) supplemented with 10% FBS, 1 mM sodium pyruvate, 100 units/ml Penicillin,
100µg/ml Streptomycin and 500µg/ml G418. Cells were transfected with the IL1RL1 plasmids in a 96-
well plate format using the TransIT-LT1 lipid transfection reagent (Mirus Bio, MIR2300) as per
manufacturer’s instructions. Empty vector (pCDH-CMV-MCS-EF1-copGFP) was used as a
transfection control and adjustments were made to correct for differences in plasmid size. Following a
24 hour period, cells were incubated for 1 hour with either 10µg/ml of either an anti-IL-33 (Invivogen,
mabg-hIL-33-3) or anti-IL1RL1 antibody (R&D, MAB523) followed by stimulation with a range of
concentrations of human recombinant IL-33 (ABNOVA, P3638). NF-KB -activated SEAP release was
measured 24 hours following IL-33 stimulation, using a commercial SEAP Reporter Assay Kit
(Invivogen, rep-sap). 10µl of cellular supernatants were used and activity measured as per
manufacturer’s instructions. For the TLR experiments, an analogous system was used, however
HEK293-NF-KB cells containing recombinant TLR2 or TLR4 prior to IL1RL1 transfection were used
and these experiments used an earlier version of the IL1RL1 TIR plasmids (in in pcDNA3.1).
Western blots
HEK293T cells stably transfected with the protective or the risk haplotype of IL1RL1 (in pcDNA3.1)
were seeded into 6 well plates (106 cells / well) in DMEM (10%FCS), cultured for 24h, followed by
serum starvation (0% FCS/DMEM) overnight. Cells were stimulated after serum starvation with IL-33
at 30 ng/ml for 0/10/20/30 minutes in DMEM (0%FCS), followed by aspiration of the media and lysis
of the cells using Laemmli buffer (200 µL per well), scraping of the well and collection of the lysate.
Lysates were immediately boiled for 10 minutes and stored at -80. Lysates were analyzed using 10%
PAA gel (home made by standard TRIS/SDS/Acrylamide/APS/TEMED) followed by transfer to
nitrocellulose using methanol-containing blotting buffer (200 Amp, 2 hours). Blocking of the
nitrocellulose is in 5% ELK/TBS, washing in 1x TBST prior to probing with total or phospho-specific
ERK1/2 antibody (respectively mAb#4695, clone 137F5; and mAb#4370; clone D13.14.4E;
CellSignallingTechnology).
Genotyping
GASP
Participants in the GASP cohort were genotyped using two platforms, 744 subjects initially genotyped
using the Affymetrix Axiom® UK BiLEVE array and 2172 subjects genotyped subsequently using the
related Affymetrix Axiom® UK Biobank array. In each genotyping batch samples were excluded if: (i)
their genetically inferred gender did not match their reported gender; (ii) they had outlying
heterozygosity within the batch (outside either 2 or 3 standard deviations from the mean depending on
batch); (iii) they had a call rate < 95% across genotyped variants; (iv) they were cryptically related to
another sample, in which case 1 sample of the pair was removed; (v) the sample shows significant
deviation from European ancestry as determined by a plot of the first two principal components. Failed
genotyping quality control excluded 380 subjects. Therefore, following exclusion of monomorphic
SNPs and SNPs only found on a single array, 692,060 SNPs were available for 2,536 subjects.
DAG
Participants in the DAG cohort were genotyped on two platforms, the Illumina 317 Chip and the
Illumina 370 Duo Chip (Illumina, San Diego, CA). Quality control (QC) was performed per chip with
exclusion of individuals with a missing genotype call rate >0.01, related individuals (identity by descent
sharing (IBS) >0.125) and non-Caucasian subjects, as assessed by principal components analysis
performed with EIGENSTRAT (15). SNPs were excluded with a missing genotype rate >0.01, a Hardy-
Weinberg equilibrium P-value <10-7 and a MAF <0.01. Markers with Mendelian errors in phase I were
excluded from analysis. Following quality control, the chips were merged and SNPs not available in
both cohorts were excluded from the dataset. A total of 294,775 SNPs remained. Imputation was
performed using IMPUTE 2.0 against the reference data set of the CEU panel from the 1000 Genomes
project (version March 2012) (16). A subset of this cohort (n=94) was selected for targeted resequencing
of the IL1RL1 gene. We developed 23 primer pairs with primer 3 software spanning the distal promoter
region, exon 1a, intron 1a, proximal promotor, exon 1b, intron 1b, exon 2, exon 3, exon 4, exon 5, intron
5, exon 5E, intron 5E, exon 6, exon 7, intron 7, exon 8, intron 8, exon 9, exon 10, intron 10 and exon
11. PCR products were Sanger-sequenced with Applied Biosystems 3730x1 DNA analyser. DNA
variants were analysed using Mutation Surveyor Software.
Lifelines Cohort
Participants of the Lifelines cohort were genotyped on the HumanCytoSNP-12 BeadChip (Illumina).
Quality control before imputation was performed using ImputationTool2, excluding SNPs with a call-
rate <95%, with a HWE-P value <0.001, MAF <0.01%. Samples were excluded in case of ambiguous
sex (genetic mismatch with reported sex), of non-Caucasian origin (based on self-report, IBS and
population stratification using EIGENSTRAT (57)), and in case a pair of samples was discovered as
first degree relatives using genetic cryptic relatedness, the sample with the best genotype quality was
included only. Imputation was performed through Beagle 3.1.0 against the CEU panel from the 1000
genomes project (version March 2012) (58).
MAAS
For the MAAS cohort, DNA was extracted from a total of 1025 individuals, who were genotyped using
the Illumina Human610-Quad array providing 2206 SNPs for analyses post QC in the chromosome 2
region.
Lung Tissue
In the Lung eQTL dataset, DNA samples were genotyped with Illumina Human1M-Duo BeadChip
arrays, and gene expression profiles were obtained using a custom Rosetta/Merck Human RSTA
Custom Affymetrix 2.0 microarray. Gene expression data are available on the Gene Expression
Omnibus accession number GSE23546 and platform GPL10379. Genotyping was completed using the
Human 1M-Duo BeadChip array (Illumina Inc, San Diego, USA) which was imputed against the 1000G
phase 1 reference panel (EUR) using IMPUTE2. Imputed SNP data were available for 1,095 of the
1,111 subjects. The final dataset included n=1088 subjects.
Bronchial brushes and biopsies
In the NORM study, genotypes have been determined using DNA from peripheral blood mononuclear
cells (PBMCs) or oral swabs using two platforms: the Human CytoSNP 12 and OmniExpress Exome
genotyping arrays (both Illumina Inc, San Diego, USA). Imputation was completed using the Haplotype
Reference Consortium Release 1.1 using the Michigan imputation server. Imputed SNP data was
available for n=72 subjects.
SureSelect bait design for region based next generation sequencing
The SureSelect method requires the design of 120 base pair oligonucleotide ‘baits’ in order to carry out
sample target enrichment. Bait design was carried out using the SureSelect™ e-array design software
available at https://earray.chem.agilent.com/earray as directed by the manufacturer.
Next-Generation DNA Sequencing (NGS).
DNA from 200 severe asthma cases (BTS 4, 5) from GASP and 200 non-asthmatic, non-atopic, non-
wheeze controls from the Nottingham Gedling cohort (5), were selected for resequencing. Subjects were
matched for age and gender (Supplemental Table 12). Next-generation Illumina sequencing of the
2q12.1 region was outsourced to Source Bioscience (Nottingham, UK) and was carried out using the
SureSelect enrichment approach. The chromosome 2 locus previously associated with asthma (17, 18)
[GRCh37.p9] was the focus and 120 base pair paired-end long read oligonucleotides (baits) were
designed using the SureSelect™ e-array design software. Bait tiling (X5) was used across the region,
presenting with a capture size range of 500Kb to 1.5Mb. The initial target region was 470,788bp; using
13,606 baits achieved 79.58% coverage of this region. Samples were pooled for sequencing (3 pools
for cases and 3 pools for controls; each set of 3 pools consisting of 66, 66 & 68 subjects). Next-
generation sequencing was carried out on these six samples on two separate lanes, one for cases and the
other for controls, using the Illumina HiSeq2000™ systems pipeline (San Diego, USA). Sequencing
used a paired end design using 100bp reads.
Following alignment to the NCBI GRCh37 genome template with Burrows-Wheeler Aligner (19), and
removal of duplicates, 14.1 million reads mapped to the 2q12.1 region, giving a mean depth of 46× per
sample. Realignment around insertion deletions and recalibration of quality scores was carried out using
the freeware software programme GATK (20), while novel variant detection was carried out using the
freeware software program Syzgy (21). In SNVer, default read mapping quality [20] and base calling
quality [17] thresholds were used for variant calling, while in Syzgy variants were detected using a
quality threshold of 10 (accuracy 90%) and compared to the NCBI SNP database (dbSNP) to determine
known variation in the region. Syzygy flags variant quality (Supplementary Table 6) as “moderate”,
“poor”, “very high” or “in cluster”, the latter indicating that there is another variant within 2bp and
hence a quality cannot be calculated.
Variant quality was obtained by both SNVer and Syzygy (Supplementary Table 1). SNVer uses the
fisher exact threshold to remove potential false positives due to allele imbalance issues, tagging variants
as ‘TRUE’ or ‘FALSE’. Syzygy flags variant quality as “moderate”, “poor”, “very high” or “in
cluster”, the latter indicating that there is another variant within 2bp and hence a quality cannot be
calculated.’ We selected variants based on positive association with asthma that were flagged as high
quality by Syzygy and ‘TRUE’ by SNVer.
Bronchial brushes and biopsies.
In the NORM study bronchial brushings and biopsies were taken from the segmental divisions of the
main bronchi in separate bronchoscopy sessions. Bronchial brushes were collected using a Cellebrity
brush (Boston Scientific, Massachusetts, USA) and analyzed for genome wide gene expression using a
Human Genome ST v1.0 micro-array. Bronchial biopsies were processed for RNA-sequencing. The
methods for RNA extraction, labeling, processing and expression quantification are described in the
Supplementary methods.
Normal Values of Inflammatory Variables From Healthy Subjects (NORM) study
RNA extraction, Sample preparation and gene expression quantification
Bronchial brushes and biopsies were taken from segmental divisions of the main bronchi in separate
bronchoscopy sessions. Brushes were analyzed for RNA expression using micro-array, biopsies were
processed for RNAsequencing.
Brushes: bronchial brushes were collected using a Cellebrity brush (Boston Scientific, Massachusetts,
USA). After collection, they were immediately placed in RNAprotect Cell Reagent (Qiagen, Venlo,
The Netherlands) and stored at −80°C. Total cellular RNA was isolated using the Qiagen total RNA 
isolation kit. Samples were then randomized, labeled, and run on Affymetrix Human Gene chip ST1.0
arrays as described previously according to manufacturer's instructions (22). Microarray analyses were
performed using R (v3.3.2) limma package and normalization was conducted in a single batch using
Robust Multi-array Average.
Biopsies: Biopsies frozen in Tissue-Tek (VWR, Radnor, PA) at -80°C were thawed at room temperature
and cut from the blocks when they were semi-solid. Total RNA was extracted using AllPrep DNA/RNA
Mini kit (Qiagen, Venlo, the Netherlands). Samples were lysed in 600µl RLT-plus buffer using an IKA
Ultra Turrax T10 Homogenizer, and RNA was purified according to the manufacturer’s instructions.
RNA samples were dissolved in 30µl RNAse free water. Concentrations and quality of RNA were
assessed using a Nanodrop-1000 and run on a Labchip GX (PerkinElmer, Waltham, MA). RNA samples
were further processed using the TruSeq Stranded Total RNA Sample Preparation Kit (Illumina, San
Diego, CA), using an automated procedure in a Caliper Sciclone NGS Workstation (PerkinElmer,
Waltham, MA). In this procedure, all cytoplasmic and mitochondria rRNA was removed (RiboZero
Gold kit). The obtained cDNA fragment libraries were loaded in pools of multiple samples onto an
Illumina HiSeq2500 sequencer using default parameters for paired-end sequencing (2 × 100 bp).
The trimmed FastQ files where aligned to build b37 of the human reference genome using HISAT
(version 0.1.5) allowing for 2 mismatches (23). Before gene quantification SAMtools (version 1.2) was
used to sort the aligned reads (24). The gene level quantification was performed by HTSeq (version
0.6.1p1) using Ensembl version 75 as gene annotation database (25).
Quality control (QC) metrics were calculated for the raw sequencing data, using the FastQC tool
(version 0.11.3) (26). QC metrics were calculated for the aligned reads using Picard-tools (version
1.130) (http://picard.sourceforge.net) CollectRnaSeqMetrics, MarkDuplicates, CollectInsertSize-
Metrics and SAMtools flagstat. In addition, we checked for concordance between sexlinked (XIST and
Y-chromosomal genes) gene expression and reported sex. All samples were concordant.
Supplemental Figures
Supplemental Figure 1. Overview of genomic region used for phenotypic association testing. The region encompasses 400kb up- and downstream of
IL1RL1 (chr2: 102,527,961-103,368,497). Figure was made with the use of Ensembl Data.21
Supplemental Figure 2. Linkage disequilibrium map of the three variants identified in Stages 1-3
and the tagging SNP for the TIR domain haplotype, with previously published asthma associated
SNPs in the chromosome 2 region. SNPs discussed in this manuscript are highlighted in blue. Figure
identifies the level of LD between signals identified based on r2 values. Image generated using the EUR
population of the Phase I cohort of the 1000 genomes study via the LDmatrix tab of the online software
tool LDlink 3.6, available at https://ldlink.nci.nih.gov/
Supplemental Figure 3. Complete analyses of baseline levels of IL1RL1 mRNA in bronchial
epithelial cells in vitro. Cells were cultured in vitro and IL1RL1 levels were stratified based on the four
selected SNPs tagging four loci of association across chromosome 2. Each row represents the mRNA
levels (qPCR) of Total – Membrane – Soluble isoforms of IL1RL1 respectively. Panels A-C represent
Locus A tagged by rs995514, D-F Locus B tagged by rs4142132, G-I Locus C tagged by rs17027258,
J-L Locus D tagged by rs10192157. Statistics run were either Mann-Whitney (Panels A-c, G-I) or
Kruskall Wallis (Panels D-F, J-L) as appropriate for two or three group comparisons. *P<0.05,
**P<0.01. Data is represented by Tukey box and whisker plots where the box covers data from the 25th
to the 75th percentiles with the centre line denoting the median of the data. Whisker plots identify the
interquartile range as determined by the Tukey method, with resulting outlier data displayed as distinct
points outside the whiskers.
Supplemental Figure 4. Complete analyses of baseline levels of soluble IL1RL1 protein in
bronchial epithelial cell supernatants. Cells were cultured in vitro and protein levels of IL1RL1
(Luminex) were stratified based on the four selected SNPs tagging four loci of association across
chromosome 2. Locus A tagged by rs995514 (A), Locus B tagged by rs4142132 (B), Locus C tagged by
rs17027258 (C), Locus D tagged by rs10192157 (D). Statistics run were either Mann-Whitney (Panels
A, B & D) or Kruskall Wallis (Panel D) as required. *P<0.05, **P<0.01. Data is represented by Tukey
box and whisker plots where the box covers data from the 25th to the 75th percentiles with the centre
line denoting the median of the data. Whisker plots identify the interquartile range as determined by
the Tukey method, with resulting outlier data displayed as distinct points outside the whiskers
Supplemental Figure 5. Complete analyses of levels of soluble IL1RL1 protein in bronchial epithelial
cell supernatants isolated from asthma patients, cultured in vitro under different asthma relevant micro-
environments and stratified based on the four selected SNPs tagging four loci of association across
chromosome 2. Column 1 presents stratification following HDM stimulation, Column 2 following IL33
stimulation (50ng/ml) and Column 3 following RV16 infection (MOI=1). Panels A-C represent Locus
A tagged by rs995514, Panels D-F represent Locus B tagged by rs4142132, Panels G-I represent Locus
C tagged by rs17027258 and Panels J-L represent Locus D tagged by rs10192157.Statistics were run
using Kruskall Wallis tests. *P<0.05, **P<0.01. Data is represented by Tukey box and whisker plots
where the box covers data from the 25th to the 75th percentiles with the centre line denoting the median
of the data. Whisker plots identify the interquartile range as determined by the Tukey method, with
resulting outlier data displayed as distinct points outside the whiskers


Supplemental Figure 6. Complete analyses of levels of IL1RL1 mRNA in bronchial epithelial cells
isolated from asthma patients and cultured in vitro under different asthma relevant micro-environments
then stratified based on the four selected SNPs tagging four loci of association across chromosome 2.
Each row represents the mRNA levels of Total – Membrane – Soluble isoforms of IL1RL1, in that
order. Panels A-I represent Locus A tagged by rs995514, Panels J-R represent Locus B tagged by
rs4142132, Panels S-AA represent Locus C tagged by rs17027258 and Panels AB-AJ represent Locus
D tagged by rs10192157. Statistics were run using Kruskall Wallis tests. *P<0.05, **P<0.01. Data is
represented by Tukey box and whisker plots where the box covers data from the 25th to the 75th
percentiles with the centre line denoting the median of the data. Whisker plots identify the interquartile
range as determined by the Tukey method, with resulting outlier data displayed as distinct points outside
the whiskers
Experiment 1. Experiment 2.
Supplemental Figure 7. Transiently transfected HEK293T cells with IL1RL1 protective or risk
haplotype. Cells were stimulated with recombinant IL33 (30 ng/ml) for 0, 10, 20 or 30 minutes as
indicated followed by lysis and Western blot analysis for total and phosphorylated ERK1/2. HEK293T
cells transfected with either IL1RL1 haplotype display an IL33 induced phosphorylation of ERK that is
largely absent in empty control cells.
A B
Supplemental Figure 8. Normalized SEAP (NF-) activity assay in TLR2 and TLR4 reporter
transfected HEK cells. TLR2 and TLR4 expressing HEK cells transiently transfected with pCDNA3.1
empty vector (negative control) or encoding the asthma risk or non-risk IL1RL1
Ala433Thr/Glu501Arg/Thr549Ile/Leu551Ser haplotypes were stimulated with a dose range of
PAM3Cys (Panel A) or LPS (Panel B), respectively. Mean values are presented for cells transiently
transfected with the empty vector, Bars represent mean+/- Standard Error of the mean.
Supplemental Figure 9: Linkage disequilibrium map of chromosome 2 illustrating LD patterns
of the three detected Signals (A-C) associated with one or more trait in the association analyses
(Stage 1). Figure identifies the level of LD between signals identified based on r2. Image generated
using the EUR population of the Phase I cohort of the 1000 genomes study via the online software tool
LDlink 3.0, available at: https://analysistools.nci.nih.gov/LDlink/?tab=home
Supplemental Figure 10: Linkage disequilibrium map of chromosome 2 illustrating location of 6
variants prioritised through Stage 2 SNP selection. Figure identifies the level of LD between signals
identified based on r2. Image generated using the EUR population of the Phase I cohort of the 1000
genomes study via the online software tool LDlink 3.0, available at:
https://analysistools.nci.nih.gov/LDlink/?tab=home
Supplemental Tables
Please see attached Excel File for Supplemental Tables 1-7.
Supplemental Table 1. Resequencing of the chromosome 2 locus. Region based resequencing of 200
UK severe asthma cases and 200 UK non-asthmatic, non-atopic controls identifies 4108 variants within
the region of which fifteen represent IL1RL1 coding region variation, rs13431828, rs201837678,
rs202037442, rs1041973, rs111970215, rs138892317, rs4988956, rs111942110, rs4988957,
rs10192036, rs10204137, rs138992262, rs4988958, rs10192157, rs10206753. Case-control association
analyses for variant association with diseases state. Using FDR<0.05 we identify 71 variants that are
associated with disease status (SNVer). OR, Odds ratio
Supplemental Table 2. Variants achieving FDR<0.05 from the resequencing of the chromosome
2 locus. Eight IL1RL1 coding variants achieve FDR<0.05 with disease status (SNVer), based off region
based resequencing of 200 UK severe asthma cases and 200 UK non-asthmatic, non-atopic controls.
Variants were identified based on case-control association analyses for variant association with diseases
state. OR, Odds ratio
Supplemental Table 3. Exon resequencing of IL1RL1. Data identifies 56 variants spanning the
IL1RL1 introns, exons and promoter region. MAF, Minor allele frequency.
Supplemental Table 4. Association results for all variants meeting initial criteria (FDR<0.05) for
association with asthma diagnosis in Lifelines. A1: Coding Allele, BP: Basepair position, FRQ:
Coding allele frequency in cohort, SE: standard error.
Supplemental Table 5. Association results for all variants meeting initial criteria (FDR<0.05) for
association with blood eosinophil levels (General Population) in Lifelines. A1: Coding Allele, BP:
Basepair position, FRQ: Coding allele frequency in cohort, SE: standard error.
Supplemental Table 6. Association results for all variants meeting initial criteria (FDR<0.05) for
association with atopy as defined by a positive response to a skin prick test in a combined meta-
analysis of the GASP and DAG cohorts. MAF, Minor allele frequency; SE, standard error.
Supplemental Table 7. Association results for all variants meeting initial criteria (FDR<0.05) for
association with lung function as defined by FEV1 in a combined meta-analysis of the GASP and
DAG cohorts. Allele 1: Coding Allele, Effect: Beta
Supplemental Table 8. Association results of chromosome 2 variation previously reported to be associated with asthma. List of chromosome 2
polymorphisms published in the literature as showing association to asthma traits. Among the asthma literature SNPs, statistically significant association of
multiple SNPs in our datasets are noted for both asthma and blood eosinophil counts in Lifelines (FDR<0.05).
*SNP also associated with blood eosinophil counts in literature (27).
SNP
POSITION
(BP)
GENE VARIANT ALLELES ANCESTRAL ALLELE ASSOCIATION FDR EFFECT SE PMID
rs1558641 102765865 5' of IL1RL1 G/A G Eos GP Lifelines 0.038 0.03 0.01 26493291
rs202011557 102913643 5' of IL1RL1 -/AAAC/AAACAAAC/AAC - - - - - 27182965
rs11685480 102927086 5' of IL1RL1 G/A - - - - -
21629437
27699235
21281963
22574108
24568840
rs6543116 102927726 5' of IL1RL1 A/G A - - - -
19852851
21629437
24568840
19254249
16118232
rs12479210 102949161 IL1RL1 C/A/T T Eos GP Lifelines 0.012 0.03 0.008
30552067
30578877
rs13431828 102954653 IL1RL1 C/T C Asthma Lifelines 0.04909 1.35 0.08
24568840
22357570
20816195
20860503
19910030
22694930
21629437
25932636
23209423
rs1041973 102955468 IL1RL1 C/A A - - - -
19910030
19852851
28266165
27699235
21281963
22574108
28273074
25091434
23999434
20816195
20860503
rs10173081 102957348 IL1RL1 C/T T Asthma Lifelines 0.04909 1.35 0.08
23028483
21804549
27699235
26102239
rs1420101* 102957716 IL1RL1 C/T T Eos GP Lifelines 0.012 0.03 0.009
18774397
21738479
19910030
23028483
21150878
20833654
19852851
26069107
21629437
27699235
21281963
22574108
21966603
20592918
25091434
24568840
20816195
20860503
19198610
rs1921622 102966067 IL1RL1 G/A A - - - -
18774397
22357570
19852851
21629437
27699235
25091434
rs10208293 102966310 IL1RL1 G/A A
Asthma Lifelines
Eos GP Lifelines
0.04909
0.012
1.22
0.03
0.06
0.01
27130862
21629437
24568840
rs10197862 102966549 IL1RL1 A/G A Asthma Lifelines 0.04909 1.34 0.08
22357570
23028483
21150878
27058054
rs1861245 102966906 IL1RL1 C/T C - - - -
19852851
21629437
rs13424006 102967236 IL1RL1 T/C C
Asthma Lifelines
Eos GP Lifelines
0.04909
0.028
1.18
0.03
0.05
0.008
24568840
rs4988958 102968285 IL1RL1 T/C T
Asthma Lifelines
Eos GP Lifelines
0.04909
0.028
1.18
0.03
0.05
0.008
22357570
rs10192157 102968356 IL1RL1 C/T C
Asthma Lifelines
Eos GP Lifelines
-0.04909
0.028
1.18
0.03
0.05
0.008
20816195
20860503
21150878
25409453
27058054
rs9807989 102971200 3` of IL1RL1 T/C T Eos GP Lifelines 0.029 0.03 0.008
23755072
22561531
rs3771166 102986222 IL18R1 G/A/T A Eos GP Lifelines 0.033 0.02 0.008
19852851
19910030
23886662
20860503
23028483
23755072
21543792
27130862
27658857
21629437
21966603
rs2310300 103049074 IL18RAP A/G A
Asthma Lifelines
Eos GP Lifelines
0.04909
0.036
1.16
0.02
0.05
0.008
20860503
22846752
Supplemental Table 9. Detailed ENCODE analyses of four priority tagging SNPs identified several putative regulatory mechanisms.
Detailed ENCODE analyses of the four selected SNPs tagging our 4 regions of association, identified several putative regulatory mechanisms. LD, linkage
disequilibrium.
*LD is based on r2>0.8, †Evidence of IL1RL1 eQTL in lung tissue.
TAGGING
SNP
SNPS IN
LD*
ENHANCER HISTONE
MARKS IN LUNG
DNASE IN LUNG PROTEINS BOUND MOTIFS CHANGED
rs12474258 6 Y N
CTCF, RAD21, MAFK,
HAE2F1
BRACHYURY, GATA, MYF, ZFP105, AP-1, HLX1, IRF,
NKX6-1, POU3F1, STAT, SP100, TCF12
rs4142132 62 Y Y
CTCF, IRF4, RAS21, SMC3,
GATA2, SETDB1, MAFK,
STAT3
IRF, AFP1, AHR::ARNT, AHR::ARNT::HIF1, AIRE, AP-1,
AP-2, ARID3A, ARID5A, ASCL2, ATF3, BARHL1, BBX, BCL,
BDP1, CART1, CDP, CDX2, CEBPB, CIZ, CTCF, DBX1,
DBX2, DMRT2, DMRT3, DMRT7, EN-1, ESX1, ETS, EVI-1,
EWSR1-FLI1, FAC1, FOX, FOXA, FOXD3, FOXF1, FOXI1,
FOXJ2, FOXL1, FOXO, FOXP1, FOXQ1, FXR, GFI1, GLI,
GM397, GR, HAND1, HAND1, HDAC2, HDX, HIF1, HMG-IY,
HNF1, HNF4, HNF6, HOXA10, HOXA3, HOXA4, HOXA5,
HOXA9, HOXB13, HOXB9, HOXC6, HSF, IK-2, IRC900814,
IRF, IRX, ISL2, ISX, LF-A1, LHX4, MAF, MEF2, MRG, MSX-
1, MYF, NANOG, NCX, NF-I, NF-KAPPAB, NKX2, NKX3,
NKX6-1, NRF-2, NRSF, P300, PAX-4, PAX-5, PAX-6, PAX7,
PBX-1, PBX3, PDX1, PHOX2A, PITX2, PLZF, POU1F1,
POU2F2, POU3F2, POU3F3, POU3F4, POU4F3, POU5F1,
POU6F1, PRDM1, PRRX1, PRRX2, PU.1, RAD21, RAR, RFX5,
RREB-1, RXRA, SMAD, SMAD3, SMC3, SOX, STAT, TAL1,
TATA, TCF12, TCF4, TGIF1, TLX1::NFIC, VAX2, VDR, YY1,
ZBTB12, ZFP105, ZFP161, ZID
rs72825929 0 N N NONE SOX
rs10192157 49 N N
GATA2, EGR1,POL2,
CTCF,SMC3,CEBPB
CTCFL,CTCF,NRSF,PTF1-BETA,STAT,ZNF263,
GR,SMAD,YY1, MEF2,TATA,MEF2,RHOX11, FOXA,HDX
,POU2F2, BCL,PRDM1,PU.1,PAX-
5,RXRA,NFAT,PRDM1,PU.1,STAT,BCL,PRDM1,PU.1,PAX5,
CDX,NKX2,NKX3,SPDEF, ZBTB3, AP-
1,FAC1,P300,AP1,FAC1,P300,AP3,GATA,POU3F1,PRDM1,PA
X-5,ROAZ,POU2F2,ROAZ,OBOX6,
DUXL,ATF3,ATF6,NKX2,FOX,FOXC1,FOXD3,FOXF1,FOXF
2,FOXI1,FOXJ1,FOXJ2,FOXK1,FOXL1,FOXO,FOXQ1,HDAC
2,SOX,ZFP105,CDX2,DMRT4,DBX1,HNF1,HOXD10,NCX,NK
X6-1,PAX4,POU2F2,SOX, ,TEF,CDC5,GR,
HOXA5,CDP,ZFP691,FAC1, CDP, ,GR,HMG-IY,RREB-
1,SOX,ZFP105, ERALPHA-
A,GFI1,LRH1,BACH2,CDX,HOXA5,IRF,SIX5,
ARID3A,BARHL1,CART1,DBX1,DBX2,EN-
1,FOXA,GR,HOXA7,HOXB4,HOXB9,ISL2,MSX-
1,NCX,NKX6-1,NKX6-2,PAX-
4,PAX7,POU1F1,POU3F4,POU4F3,SOX, CEBPB,ERALPHA-
A,PLZF,RAR,RXRA,VDR, AHR,HEY1, GR, ESR2, EBF,SZF1-
1,ZEB1, CART1, IRF,POU2F2, IRF,POU2F2, HDAC2,IK-2,NF-
AT1,POU2F2,STAT, FOXP3,IRF,STAT,
ARID5B,MRG,PLZF,RXR::LXR, HNF1,HNF4,IRF,PAX-
4,RREB-1, PU.1,SIN3AK-20, RREB-1,UF1H3BETA,
CDP,GR,HNF1, HNF1,IK-2, BBX,POU5F1,SIX5
Supplemental Table 10. Demographics of the GASP, DAG and Lifelines cohorts used independently and together (GASP & DAG) for genetic association
analyses. Percentage values are presented as percent of valid subjects.
Characteristics
GASP
(N=2536)
N DAG (N=909) N
Lifelines Asthma
(N=1066)
N
Lifelines Control
(N=6863)
N
Age (yrs), mean (SD) 47.83 (15.51) 2285 34.78 (15.80) 909 46.2 (10.9) 1066 49.2 (11.9) 6863
Gender, Male (%) 36.0 2534 46.9 909 40.2 1066 46.8 6863
Height (m), mean (SD) 1.66 (0.10) 2095 1.68 (0.16) 905 1.80 (0.10) 1066 1.75 (0.09) 6863
FEV1 (L), mean (SD) 2.26 (0.85) 2089 2.81 (0.94) 899 3.1 (0.8) 1066 3.4 (0.8) 6863
FEV1/FVC, mean (SD) 0.69 (0.14) 1931 0.79 (0.10) 262 0.73 (0.09) 1066 0.77 (0.7) 6863
Blood Eosinophils (10-
9/L), median (range)
0.31 (0.00-5.42) 1018 0.23 (0.00-1.90) 769 0.20 (0.13-0.30) 1066 0.15 (1.10-0.22) 6863
Total IgE (kU/L), median
(range)
406.79 (1.00 –
5000.00)
1379
378.41 (0.00 –
12400.00)
772 ND ND ND ND
Atopy* (%) 1072 (68.5) 1559 578 (85.4) 677 ND ND ND ND
Age of asthma onset
(yrs), mean (SD)
23.20 (17.95) 1178 10.07 (10.58) 689 ND ND ND ND
Childhood onset asthma 578 (46.2) 1284 520 (75.5) 689 ND ND ND ND
N = number of subjects data field available for, SD: Standard of Deviation, ND = Not Determined/Defined
*Atopy was based on at least one positive response to intracutaneous or skin prick tests (SPT) †Childhood onset asthma defined as a diagnosis occurring before
the age of 16.
Supplemental Table 11. Demographics for the asthma patients taken from DAG (95 cases) used in the
next-generation sequencing of the chromosome 2 locus.
Characteristics DAG (n=95) N
Age (yrs), mean (SD) 33.89 (14.5) 95
Gender, Male (%) 36.8% 95
Height (m), mean (SD) 1.74 (0.09) 95
Smoking (%)
Current
Ex
Never
10.6%
33.0%
56.4%
94
Smoking (pky) 8.67 (6.8) 40
Steroid use
ICS only
ICS+OCS
No CS
80%
2.1%
17.9%
95
Reversibility (%pred) qual
>9
<9
43.6%
56.4%
94
FEV1 prebd (L), mean (SD)
%pred
3.29 (0.74)
90.3%
94
FEV1/FVC, mean (SD)
0.77 (0.11)
94
Blood Eosinophils (10-9/L), median (range) 0.16 (0.001-0.64) 95
Total IgE (kU/L), median (range) 504.63 (3.0-8650.0) 95
Atopy* (%) 79 (84.9%) 93
Age of asthma onset (yrs), mean (SD) - -
Childhood onset asthma - -
N = number of subjects data field available for, SD: Standard of Deviation, ND = Not
Determined/Defined. *Atopy was based on at least one positive response to intracutaneous or skin prick
tests (SPT) †Childhood onset asthma defined as a diagnosis occurring before the age of 16.
Supplemental Table 12. Demographics for the sub-cohorts taken from GASP (200 cases) and
GEDLING (5) (200 non-asthmatic, non-atopic controls) used in the next-generation sequencing of the
chromosome 2 locus.
Characteristics GASP Cohort (cases) Gedling Cohort (controls)
Age (yrs), mean (SD) 48 (14.88) 57 (12.64)
Gender, Male (%) 30.6 27.0
Height (m), mean (SD) 1.64 (0.08) 1.66 (0.06)
FEV1 (L), mean (SD 2.17 (0.84) 2.77 (0.79)
Smoking pack/years 11.82 (20.25) 8.40 (18.61)
Never Smokers (%) 52.0 53.5
Supplemental Table 13. Demographics of the Manchester Asthma and Allergy Study at age 8 years
Characteristics MAAS (N=919) N
Age (yrs), mean (SD) 7.98 (0.16) 919
Gender, Male (%) 53.8 919
Height (cm) , mean (SD) 128.2 (5.61) 919
FEV1 (L), mean (SD) 1.59 (0.25) 695
FEV1/FVC, mean (SD) 0.87 (0.06) 695
Atopy, number (%) 32.9 817
Asthma, number (%) 23.9 872
Supplemental Table 14. Expression quantitative trait loci (eQTL) analysis for tagging SNPs or proxies
in a dataset in bronchial biopsy (n=77) and bronchial brushes (n=72) from healthy individuals.
Bronchial biopsy Bronchial brushing
Signal/SNP (C/NC*) MAF Beta SE Pval Beta SE Pval
A rs10167431† G/A 0.44 -0.01 0.17 0.93 -0.01 0.06 0.87
B rs10178436†† G/A 0.45 0.01 0.19 0.97 -0.07 0.06 0.29
C rs2241116††† C/A 0.17 -0.11 0.25 0.66 0.04 0.07 0.62
D rs10192157 G/A 0.32 -0.09 0.16 0.55 -0.02 0.05 0.64
*SNPs are reported in relation to the linkage disequilibrium (LD) blocks (r2>0.8) reported in this study.
TAO: Time to asthma onset
†Variants relate to the variants subsequently selected as tagging SNPs for functional studies.
No SNPs were identified as eQTLs in this dataset. *C=coded allele, NC=Non-coded allele, †rs10167431
was used as a proxy for rs12474258 (r2=0.68), ††rs10178436 was used as a proxy for rs4142132
(r2=0.98), †††rs2241116 was used as a proxy for rs72825929 (r2=0.37), MAF= Minor allele frequency
Supplemental Table 15. Demographics for donors of bronchial epithelial cells contributing to the
AHBEC dataset.
*Atopy was defined as a positive response to a skin prick test. Data was not available for the full cohort
of 51 individuals.
Characteristics AHBEC (N=51) N
Age (yrs), mean (SD) 50 (13.47) 20
Gender, Male (%) 43.5 23
Height (m), mean (SD) 1.71 (0.10) 13
FEV1 (L), mean (SD) 2.70 (0.95) 25
FEV1/FVC , mean (SD) 0.69 (0.11) 19
Atopy*, number (%) 7 (58.3) 12
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